根治性放疗后复发前列腺癌的挽救性高剂量率近距离治疗
该回顾性研究纳入129例根治性放疗后局部复发前列腺癌患者,接受全腺体挽救性高剂量率近距离治疗(sHDRBT)。中位随访68个月,3年和5年无病生存率分别为85%和71%,≥35%阳性穿刺针数且无病间期<4.1年者生化控制较差。sHDRBT是合理选择,但需注意泌尿系统毒性。
要点
- sHDRBT后3年和5年无病生存率分别为85%和71%。
- ≥35%阳性针数且无病间期<4.1年者生化控制更差(19% vs 50%)。
- 急性尿路梗阻需留置导尿11%,尿道狭窄需扩张15%。
核心结论
- sHDRBT是根治性放疗后局部复发前列腺癌的合理治疗选择。
- 阳性穿刺针数<35%或无病间期≥4.1年的患者可能更易获得长期疾病控制。
研究设计与样本
- 回顾性分析1998年至2016年接受全腺体sHDRBT的129例患者。
- 评估与生化控制相关的临床因素及毒性。
主要发现
- sHDRBT后中位随访68个月,3年和5年无病生存率分别为85%(95% CI 79-91)和71%(95% CI 62-79)。
- 中位PSA最低值为0.18 ng/mL,于sHDRBT后中位10个月达到。
- 局部失败(伴或不伴区域/远处失败)见于11%(14/129)的患者。
- 14例(11%)发生需留置Foley导尿管的急性尿路梗阻,19例(15%)发生需扩张的尿道狭窄。
关键数值与推荐
- 诊断时中位PSA为7.77 ng/mL,多数患者为T1-2(73%)和Gleason 6-7(82%)疾病。
- 71%既往接受单纯外照射放疗,22%接受永久性前列腺植入。
- 中位无病间期为56个月,挽救治疗前中位PSA为4.95 ng/mL。
- sHDRBT时46%为T3疾病,51%为Gleason 8-10疾病。
临床怎么用
- sHDRBT可用于根治性放疗后局部复发前列腺癌,但应筛选阳性针数<35%或无病间期≥4.1年的患者。
- 治疗前应告知患者急性尿路梗阻和尿道狭窄的风险。
局限性
- 回顾性单中心研究,样本量129例,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Salvage high-dose-rate brachytherapy (sHDRBT) for locally recurrent prostate cancer after definitive radiation is associated with biochemical control in approximately half of patients at 3 to 5 years. Given potential toxicity, patient selection is critical. We present our institutional experience with sHDRBT and validate a recursive partitioning machines model for biochemical control. MATERIALS AND METHODS: We performed a retrospective analysis of 129 patients who underwent whole-gland sHDRBT between 1998 and 2016. We evaluated clinical factors associated with biochemical control as well as toxicity. RESULTS: At diagnosis the median prostate-specific antigen (PSA) was 7.77 ng/mL. A majority of patients had T1-2 (73%) and Gleason 6-7 (82%) disease; 71% received external beam radiation therapy (RT) alone, and 22% received permanent prostate implants. The median disease-free interval (DFI) was 56 months, and median presalvage PSA was 4.95 ng/mL. At sHDRBT, 46% had T3 disease and 51% had Gleason 8 to 10 disease. At a median of 68 months after sHDRBT, 3- and 5-year disease-free survival were 85% (95% CI, 79-91) and 71% (95% CI, 62-79), respectively. Median PSA nadir was 0.18 ng/mL, achieved a median of 10 months after sHDRBT. Patients with ≥35%+ cores and a DFI <4.1 years had worse biochemical control (19% vs 50%, P = .02). Local failure (with or without regional/distant failure) was seen in 11% of patients (14/129), and 14 patients (11%) developed acute urinary obstruction requiring Foley placement and 19 patients (15%) developed strictures requiring dilation. CONCLUSIONS: sHDRBT is a reasonable option for patients with locally recurrent prostate cancer after definitive RT. Those with <35%+ cores or an initial DFI of ≥4.1 years may be more likely to achieve long-term disease control after sHDRBT.
引用
- Wu SY, Wong AC, Shinohara K, et al. Salvage High-Dose-Rate Brachytherapy for Recurrent Prostate Cancer After Definitive Radiation. Pract Radiat Oncol. 2021. PMID: 34077809. doi:10.1016/j.prro.2021.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。